Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ixekizumab Q4W · 1 trial · 1 indication
ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).
| Arm | Type | Description |
|---|---|---|
| Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W) | EXPERIMENTAL | Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks). |
| Ixekizumab 80 mg Q4W | EXPERIMENTAL | Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks). |
| Placebo | PLACEBO_COMPARATOR | Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks). |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered SC |
| Ixekizumab 80 mg Q4W | DRUG | Administered SC |
| Ixekizumab 80 mg Q2W | DRUG | Administered SC |
Inclusion Criteria: * Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria * Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints * Presence of act...
Top 11 of 12 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 4 | PHASE3 | Zasocitinib |
| Johnson & Johnson | JNJ | 9 | PHASE3 | Guselkumab, Ustekinumab, Icotrokinra, JNJ-88545223 |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab, Adalimumab, Lutikizumab |
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Deucravacitinib |
| MoonLake Immunotherapeutics Class A | MLTX | 3 | PHASE3 | Sonelokimab |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Ixekizumab, Tirzepatide |
| Amgen Inc. | AMGN | 2 | PHASE3 | Apremilast |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE1 | Secukinumab |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Pfizer Inc. | PFE | 2 | - | tofacitinib |
Ixekizumab Q4W is an investigational dosing regimen of ixekizumab studied for the treatment of active psoriatic arthritis in adults. It refers to an 80 mg dose given every four weeks. The regimen has been evaluated in a Phase 3 clinical trial in participants with active psoriatic arthritis.
Ixekizumab Q4W targets interleukin-17A (IL17A). It is a monoclonal antibody that acts as an inhibitor of this cytokine. By binding to IL17A, it is designed to block the inflammatory signaling pathway implicated in psoriatic arthritis.
Ixekizumab Q4W is being developed by Eli Lilly and Company, which trades under the ticker symbol LLY. Eli Lilly is the sponsor of the clinical program evaluating this dosing regimen in psoriatic arthritis.
Ixekizumab Q4W is in Phase 3 clinical development for psoriatic arthritis. The program includes one completed Phase 3 trial. It is an investigational regimen and has not been approved by the FDA for this use.
Ixekizumab Q4W has been studied in the Phase 3 trial NCT02349295, titled "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis." The trial enrolled 363 participants, was randomized, double-blind, and placebo-controlled, and has been completed.